| Dr Stephen Dolan, MD | |
|
9200 W Wisconsin Ave, Division Of Pulmonary Diseases, Milwaukee, WI 53226 | |
| (414) 805-6633 | |
| (414) 805-3859 |
| Full Name | Dr Stephen Dolan |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 36 Years |
| Location | 9200 W Wisconsin Ave, Milwaukee, Wisconsin |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144274465 | NPI | - | NPPES |
| 32468600 | Medicaid | WI | |
| 002000328T | Other | HUMANA | |
| 1144274465 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 40320 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Froedtert Memorial Lutheran Hospital | Milwaukee, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Medical College Of Wisconsin Inc | 2668384371 | 1813 |
News Archive
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that enrollment has commenced in its Phase 2b, open-label, safety and efficacy positron emission tomography imaging study of [18F]NAV4694 for detection of cerebral β-amyloid plaque in subjects diagnosed with Mild Cognitive Impairment.
Many pediatricians know their patients use complementary and alternative therapies (CAM) to improve their health, yet most do not feel comfortable discussing or recommending these therapies, according to a study published in the November issue of Ambulatory Pediatrics.
A new study by an international team of investigators led by Dana-Farber Cancer Institute scientists is the first to demonstrate that chemotherapy and a new, targeted therapy work better in combination than chemotherapy alone in treating patients with the most common genetic subtype of lung cancer.
A new reversible blood thinner for angioplasty patients wasn't superior over placebo for its primary combined endpoint of heart attack, all-cause mortality and need for revascularization, but it reduced mortality and in-stent blood clots, researchers reported in a late-breaking clinical trial presentation at the American Heart Association's Scientific Sessions 2009.
New Rhode Island regulations that took effect on Sunday require state hospitals to provide no-cost care to any uninsured resident whose income is at or below 200% of the federal poverty level, the Providence Journal reports.
› Verified 2 days ago
| Entity Name | The Medical College Of Wisconsin Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699720086 PECOS PAC ID: 2668384371 Enrollment ID: O20031120000259 |
News Archive
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that enrollment has commenced in its Phase 2b, open-label, safety and efficacy positron emission tomography imaging study of [18F]NAV4694 for detection of cerebral β-amyloid plaque in subjects diagnosed with Mild Cognitive Impairment.
Many pediatricians know their patients use complementary and alternative therapies (CAM) to improve their health, yet most do not feel comfortable discussing or recommending these therapies, according to a study published in the November issue of Ambulatory Pediatrics.
A new study by an international team of investigators led by Dana-Farber Cancer Institute scientists is the first to demonstrate that chemotherapy and a new, targeted therapy work better in combination than chemotherapy alone in treating patients with the most common genetic subtype of lung cancer.
A new reversible blood thinner for angioplasty patients wasn't superior over placebo for its primary combined endpoint of heart attack, all-cause mortality and need for revascularization, but it reduced mortality and in-stent blood clots, researchers reported in a late-breaking clinical trial presentation at the American Heart Association's Scientific Sessions 2009.
New Rhode Island regulations that took effect on Sunday require state hospitals to provide no-cost care to any uninsured resident whose income is at or below 200% of the federal poverty level, the Providence Journal reports.
› Verified 2 days ago
| Entity Name | Froedtert &the Medical College Of Wisconsin Community Physicians Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568787448 PECOS PAC ID: 3678760063 Enrollment ID: O20101210000699 |
News Archive
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that enrollment has commenced in its Phase 2b, open-label, safety and efficacy positron emission tomography imaging study of [18F]NAV4694 for detection of cerebral β-amyloid plaque in subjects diagnosed with Mild Cognitive Impairment.
Many pediatricians know their patients use complementary and alternative therapies (CAM) to improve their health, yet most do not feel comfortable discussing or recommending these therapies, according to a study published in the November issue of Ambulatory Pediatrics.
A new study by an international team of investigators led by Dana-Farber Cancer Institute scientists is the first to demonstrate that chemotherapy and a new, targeted therapy work better in combination than chemotherapy alone in treating patients with the most common genetic subtype of lung cancer.
A new reversible blood thinner for angioplasty patients wasn't superior over placebo for its primary combined endpoint of heart attack, all-cause mortality and need for revascularization, but it reduced mortality and in-stent blood clots, researchers reported in a late-breaking clinical trial presentation at the American Heart Association's Scientific Sessions 2009.
New Rhode Island regulations that took effect on Sunday require state hospitals to provide no-cost care to any uninsured resident whose income is at or below 200% of the federal poverty level, the Providence Journal reports.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Stephen Dolan, MD 9200 W Wisconsin Ave, Division Of Pulmonary Diseases, Milwaukee, WI 53226-3522 Ph: (414) 805-6633 | Dr Stephen Dolan, MD 9200 W Wisconsin Ave, Division Of Pulmonary Diseases, Milwaukee, WI 53226 Ph: (414) 805-6633 |
News Archive
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that enrollment has commenced in its Phase 2b, open-label, safety and efficacy positron emission tomography imaging study of [18F]NAV4694 for detection of cerebral β-amyloid plaque in subjects diagnosed with Mild Cognitive Impairment.
Many pediatricians know their patients use complementary and alternative therapies (CAM) to improve their health, yet most do not feel comfortable discussing or recommending these therapies, according to a study published in the November issue of Ambulatory Pediatrics.
A new study by an international team of investigators led by Dana-Farber Cancer Institute scientists is the first to demonstrate that chemotherapy and a new, targeted therapy work better in combination than chemotherapy alone in treating patients with the most common genetic subtype of lung cancer.
A new reversible blood thinner for angioplasty patients wasn't superior over placebo for its primary combined endpoint of heart attack, all-cause mortality and need for revascularization, but it reduced mortality and in-stent blood clots, researchers reported in a late-breaking clinical trial presentation at the American Heart Association's Scientific Sessions 2009.
New Rhode Island regulations that took effect on Sunday require state hospitals to provide no-cost care to any uninsured resident whose income is at or below 200% of the federal poverty level, the Providence Journal reports.
› Verified 2 days ago
Julia Bonner, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 3351 North Downer Avenue, Milwaukee, WI 53211 Phone: 414-229-5684 | |
Dr. Zachary Smith, DO Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 9200 W Wisconsin Ave, Milwaukee, WI 53226 Phone: 414-955-6830 Fax: 414-955-6214 | |
Dr. Christopher Patrick Boyd, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 9200 W Wisconsin Ave, Milwaukee, WI 53226 Phone: 414-805-6000 Fax: 414-805-6280 | |
Umair Bajwa, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 9200 W Wisconsin Ave, Milwaukee, WI 53226 Phone: 414-805-0812 Fax: 414-805-0855 | |
Dr. Jeffrey Wilson, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1020 N 12th St, Ste 206, Milwaukee, WI 53233 Phone: 414-219-7136 | |
Rasika Surajyam Chepuri, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 9200 W Wisconsin Ave, Milwaukee, WI 53226 Phone: 414-955-7040 Fax: 414-955-6211 | |
Soryal A Soryal, M.D Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1020 N 12th St, 3rd Floor, Milwaukee, WI 53233 Phone: 414-219-7300 |